ArticlePregnancy (Hoboken, N.J.)2026
Association of treatment for prenatal depression with cardiovascular disease within 24 months after delivery.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: While the strong association of prenatal depression with an increased risk of new cardiovascular disease (CVD) within 24 months postpartum has been demonstrated in two distinct cohorts, it is unclear if treatment of prenatal depression may mitigate this risk. We aimed to estimate the cumulative risk of new CVD and new chronic hypertension in the first 24 months postpartum among pregnant individuals with prenatal depression treated with antidepressant medications or psychotherapy compared with those with untreated prenatal depression. We hypothesized that treatment for prenatal depression may be associated with a lower risk of CVD postpartum among those with prenatal depression. Methods: Our longitudinal population-based study included pregnant individuals with deliveries in the Maine Health Data Organization's All Payer Claims Data during 2007-2020. We excluded those individuals with any diagnosis before pregnancy of the cardiovascular conditions being examined postpartum, multifetal gestations, or no continuous health insurance during pregnancy. Prenatal depression, psychotherapy, and antidepressant medications were identified with ICD9/10 diagnosis codes, CPT codes, and pharmacy dispensing data, respectively. Primary outcomes were a dichotomous CVD composite (heart failure, ischemic heart disease, cerebrovascular disease, arrhythmia/cardiac arrest, cardiomyopathy) and chronic hypertension within 24 months postpartum. Adjusted Cox models were used to estimate hazard ratios. Results: Among the 17,100 pregnant individuals with depression included in our analysis (13.5% of 126,333 total eligible pregnancies), 50.0% ( Conclusion: The cumulative risk of new CVD within 24 months postpartum was significantly lower in patients with antidepressant and/or psychotherapy use during pregnancy compared to those with untreated prenatal depression. This suggests that treatment of prenatal depression may mitigate CVD risk; however, given the limitations of observational research, further study is warranted to elucidate the pathophysiologic mechanisms that underlie this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.